Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is designed as an open-label evaluation of how treatment with XR-NTX may influence
the quality and speed of recovery of opioid dependent individuals - in a context of a
naturalistic clinical treatment of opioid dependence. The study will assess recovery outcomes
and compare these with the clinical effectiveness of XR-NTX (use of illicit substances and
safety). Further, the study will assess the recovery outcomes in matched controls receiving
treatment with buprenorphine or buprenorphine-naloxone and enrolled in the national OMT
program, and compare this with participants receiving XR-NTX.
Phase:
Phase 4
Details
Lead Sponsor:
Lars Tanum
Collaborators:
Haukeland University Hospital Hospital of Southern Norway Trust The Hospital of Vestfold